Retrospective analysis of patients with hepatocellular carcinoma complicated with human immunodeficiency virus infection after hepatectomy

Table 1 Clinical data for patients in the surgery group

Indicator	n = 27
Age (years)	60.15 ± 5.90
Gender (Male:female)	24:3
HIV initial diagnosis, n (%)	20 (74.1)
HIV-RNA positive, n (%)	13 (48.1)
MSM, n (%)	18 (66.7)
Received HART after HIV diagnosis	21 (77.8)
HBV, n (%)	21 (77.8)
HCV, n (%)	2 (7.4)
Chronic alcohol consumption, n (%)	11 (40.7)
PS score (0-1:2-3)	16:11
CD4+ cell count < 200 (cell/μL)	15 (55.6)
Child-Pugh score (A:B)	21:6
BCLC staging (0-B:C-D)	10:17
CNLC Staging (Ia-IIa:IIb-IIIa)	18:9
AFP (ng/mL)	249.00 (3.56-2287.42)
ALT (U/L)	31.48 ± 22.39
AST (U/L)	37.44 ± 26.24
TBIL	16.31 ± 9.37
DBIL	5.62 ± 4.15
IBIL	10.68 ± 6.53
Prothrombin time (second)	13.55 ± 2.35
Albumin	36.88 ± 5.36
Hemoglobin	135.11 ± 13.37
White blood cell count (/L)	4.84 ± 1.66
Platelet count (/L)	127.11 ± 91.61
Tumor maximum diameter (mm)	46 (15-130)
Tumor solitary:multiple	10:17
Hepatic encephalopathy (n)	0
Ascites, n (%)	11 (40.7)
Intraoperative blood loss (50-200:300-500)	19: 8
Hepatic artery embolization, n (%)	12 (44.4)
Postoperative recurrence and retreatment, n (%)	12 (44.4)
Postoperative MVI	8 (29.6)
Tumor capsule, n (%)	12 (44.4)
PDL1 positive, n (%)	17 (63.0)

HART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; MSM: Men who have sex with men; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; MVI: Microvascular invasion.